|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Ironwood Pharmaceuticals, Inc.
| | | Phone: | (617) 621-7722 | Fax: | (617) 494-0908 | Year Established: | 1998 | Ticker: | IRWD | Exchange: | NASDAQ | Main Contact: | Tom McCourt, CCO & Senior VP, Marketing & Sales | | Other Contacts: | Brian Cali, Co-Founder & Senior VP, R&D Strategy and External Innovation Michael Hall, Senior VP, Clinical Development Mark G. Currie, Ph.D., Senior VP, R&D & CSO Halley Gilbert, Esq., VP, Legal Affairs and General Counsel Tom Graney, CFO Peter M. Hecht, Ph.D., CEO
| | Company Description | Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company
dedicated to the art and science of great drugmaking. LINZESS (linaclotide), Ironwood’s guanylate cyclase-C (GC-C) agonist, is an FDA-approved drug for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. | |
|
|
|
|
|